Altamira Therapeutics Ltd. (NASDAQ:CYTO – Get Free Report) dropped 25.9% during mid-day trading on Thursday . The company traded as low as $0.30 and last traded at $0.30. Approximately 753,013 shares were traded during trading, an increase of 8% from the average daily volume of 697,326 shares. The stock had previously closed at $0.41.
Altamira Therapeutics Price Performance
The company has a 50-day moving average of $0.40 and a 200-day moving average of $0.73.
About Altamira Therapeutics
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.
Featured Articles
- Five stocks we like better than Altamira Therapeutics
- What Are Dividend Achievers? An Introduction
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- How to buy stock: A step-by-step guide for beginners
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
